Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report

Figures & data

Figure 1. Clinical photos demonstrated resolution of eczematous cirAE throughout treatment with ruxolitinib 1.5% cream on the following days: (A) Day 96; pre-ruxolitinib 1.5% cream, (B) Day 100; day two of ruxolitinib 1.5% cream, (C) Day 104; day six of ruxolitinib 1.5% cream, (D) Day 127; day 29 of ruxolitinib 1.5% cream.